Masked Primary Hyperparathyroidism by Empagliflozin Use.
antidiabetic drugs
empagliflozin
hypercalcemia
hyperparathyroidism
masked primary hyperparathyroidism
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
26
04
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Sodium-glucose cotransporter-2 inhibitors are drugs that regulate blood sugar by decreasing glucose reabsorption from the proximal renal tubules. Primary hyperparathyroidism masked by empagliflozin is very rare and only a few cases are reported in the literature. We report a case of a 57-year-old man with a known history of diabetes on empagliflozin for two years who presented with hypercalcemia and equivocal parathyroid hormone level. Upon cessation of this medication, he had persistent hypercalcemia with a raised parathyroid level, which confirmed the diagnosis of primary hyperparathyroidism. We believe this case is one of the first cases reported in the literature.
Identifiants
pubmed: 35651422
doi: 10.7759/cureus.24488
pmc: PMC9135599
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e24488Informations de copyright
Copyright © 2022, Awada et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669938
Nat Rev Nephrol. 2017 Jan;13(1):11-26
pubmed: 27941935
JBMR Plus. 2019 Nov 04;3(11):e10242
pubmed: 31768494
AACE Clin Case Rep. 2021 Jul 12;8(1):30-33
pubmed: 35097199
Diabetes Metab Syndr. 2018 Jan - Mar;12(1):59-63
pubmed: 28826578
Diabetologia. 2016 Dec;59(12):2546-2551
pubmed: 27628105
AACE Clin Case Rep. 2020 Aug 06;6(6):e319-e321
pubmed: 33244493
Endocrinol Diabetes Metab Case Rep. 2015;2015:150042
pubmed: 26191411
Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73
pubmed: 30559106